BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28393359)

  • 1. Metformin and the incidence of viral associated cancers in patients with type 2 diabetes.
    Hicks BM; Yin H; Sinyavskaya L; Suissa S; Azoulay L; Brassard P
    Int J Cancer; 2017 Jul; 141(1):121-128. PubMed ID: 28393359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus.
    Tseng CH
    Diabetes Metab Res Rev; 2015 Sep; 31(6):619-26. PubMed ID: 25820555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
    Tseng CH
    Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of metformin and risk of kidney cancer in patients with type 2 diabetes.
    Tseng CH
    Eur J Cancer; 2016 Jan; 52():19-25. PubMed ID: 26630530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin use and survival after colorectal cancer: A population-based cohort study.
    Mc Menamin ÚC; Murray LJ; Hughes CM; Cardwell CR
    Int J Cancer; 2016 Jan; 138(2):369-79. PubMed ID: 26331456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes.
    Tseng CH
    Acta Diabetol; 2014 Apr; 51(2):295-303. PubMed ID: 24509842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting.
    Geraldine N; Marc A; Carla T; Chantal M; Stefaan B; Welcome W; Frank B
    Diabetes Res Clin Pract; 2012 Aug; 97(2):331-6. PubMed ID: 22386769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study.
    Calip GS; Yu O; Elmore JG; Boudreau DM
    Cancer Causes Control; 2016 May; 27(5):709-20. PubMed ID: 27053250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.
    Tsilidis KK; Capothanassi D; Allen NE; Rizos EC; Lopez DS; van Veldhoven K; Sacerdote C; Ashby D; Vineis P; Tzoulaki I; Ioannidis JP
    Diabetes Care; 2014 Sep; 37(9):2522-32. PubMed ID: 24898303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.
    Tseng CH
    Oncotarget; 2017 Mar; 8(12):18802-18810. PubMed ID: 27861146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin use and cervical cancer risk in female patients with type 2 diabetes.
    Tseng CH
    Oncotarget; 2016 Sep; 7(37):59548-59555. PubMed ID: 27486978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan.
    Tseng CH
    Gynecol Oncol; 2015 Jul; 138(1):147-53. PubMed ID: 25913129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidiabetic Medication, Statins and the Risk and Prognosis of Non-endometrioid Endometrial Cancer in Women with Type 2 Diabetes.
    Arima R; Marttila M; Hautakoski A; Arffman M; Sund R; Ilanne-Parikka P; Kangaskokko J; Urpilainen E; Läärä E; Hinkula M; Puistola U
    Anticancer Res; 2018 Jul; 38(7):4169-4178. PubMed ID: 29970546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes.
    Arima R; Marttila M; Hautakoski A; Arffman M; Sund R; Ilanne-Parikka P; Kangaskokko J; Läärä E; Puistola U; Hinkula M
    Gynecol Oncol; 2017 Sep; 146(3):636-641. PubMed ID: 28645427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin reduces the risk of cancer in patients with type 2 diabetes: An analysis based on the Korean National Diabetes Program Cohort.
    Kim HJ; Lee S; Chun KH; Jeon JY; Han SJ; Kim DJ; Kim YS; Woo JT; Nam MS; Baik SH; Ahn KJ; Lee KW
    Medicine (Baltimore); 2018 Feb; 97(8):e0036. PubMed ID: 29465545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer.
    Park YM; Bookwalter DB; O'Brien KM; Jackson CL; Weinberg CR; Sandler DP
    Ann Oncol; 2021 Mar; 32(3):351-359. PubMed ID: 33516778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin and lung cancer risk in patients with type 2 diabetes mellitus.
    Tseng CH
    Oncotarget; 2017 Jun; 8(25):41132-41142. PubMed ID: 28456789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
    Yu OH; Yin H; Azoulay L
    Can J Diabetes; 2015 Oct; 39(5):383-9. PubMed ID: 25840943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
    Kowall B; Stang A; Rathmann W; Kostev K
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):865-74. PubMed ID: 26132313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.